Clinical Trial Update: Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing anlotinib in combination with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma is ongoing, with status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN